AU2022386164A1 - Protein tyrosine phosphatase inhibitors and methods of use thereof - Google Patents

Protein tyrosine phosphatase inhibitors and methods of use thereof Download PDF

Info

Publication number
AU2022386164A1
AU2022386164A1 AU2022386164A AU2022386164A AU2022386164A1 AU 2022386164 A1 AU2022386164 A1 AU 2022386164A1 AU 2022386164 A AU2022386164 A AU 2022386164A AU 2022386164 A AU2022386164 A AU 2022386164A AU 2022386164 A1 AU2022386164 A1 AU 2022386164A1
Authority
AU
Australia
Prior art keywords
hydroxy
dihydro
benzothiopyran
fluoro
trione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022386164A
Other languages
English (en)
Inventor
Andrew Bogdan
Christos ECONOMOU
Jennifer M. Frost
Philip R. Kym
Spencer O. Scholz
Zhaoming Xiong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Calico Life Sciences LLC
Original Assignee
AbbVie Inc
Calico Life Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc, Calico Life Sciences LLC filed Critical AbbVie Inc
Publication of AU2022386164A1 publication Critical patent/AU2022386164A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2022386164A 2021-11-11 2022-11-10 Protein tyrosine phosphatase inhibitors and methods of use thereof Pending AU2022386164A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163278336P 2021-11-11 2021-11-11
US63/278,336 2021-11-11
PCT/US2022/049581 WO2023086495A1 (en) 2021-11-11 2022-11-10 Protein tyrosine phosphatase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2022386164A1 true AU2022386164A1 (en) 2024-05-23

Family

ID=84887566

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022386164A Pending AU2022386164A1 (en) 2021-11-11 2022-11-10 Protein tyrosine phosphatase inhibitors and methods of use thereof

Country Status (8)

Country Link
US (1) US20250042894A1 (https=)
EP (1) EP4430039A1 (https=)
JP (1) JP2024543451A (https=)
CN (1) CN118556055A (https=)
AU (1) AU2022386164A1 (https=)
CA (1) CA3236853A1 (https=)
MX (1) MX2024005656A (https=)
WO (1) WO2023086495A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20252789A1 (es) 2023-05-24 2025-12-22 Kumquat Biosciences Inc Compuestos heterociclicos y usos de estos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
BR112020026086A2 (pt) * 2018-06-21 2021-03-23 Calico Life Sciences Llc inibidores da proteína tirosina fosfatase e métodos de uso destes
IL286373B2 (en) * 2019-03-14 2026-03-01 Calico Life Sciences Llc Protein tyrosine phosphate inhibitor compounds and uses thereof
CA3162069A1 (en) * 2019-12-18 2021-06-24 Elliot P. Farney Protein tyrosine phosphatase inhibitors and methods of use thereof

Also Published As

Publication number Publication date
US20250042894A1 (en) 2025-02-06
MX2024005656A (es) 2024-08-06
CA3236853A1 (en) 2023-05-19
EP4430039A1 (en) 2024-09-18
WO2023086495A1 (en) 2023-05-19
JP2024543451A (ja) 2024-11-21
CN118556055A (zh) 2024-08-27

Similar Documents

Publication Publication Date Title
US12227484B2 (en) Inhibitors of PARG
EP3580224B1 (en) Ask1 inhibiting agents
KR20210016344A (ko) 신규한 화합물
AU2017339249A1 (en) Substituted pyrrolidines and their use in the treatment of cystic fiibrosis
EP3865474A1 (en) Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
EP4507691A2 (en) Jak inhibitor analogs, formulations, and uses thereof
JP6807054B2 (ja) 環状アミン誘導体及びその医薬用途
EP4107153A1 (en) Compounds
TW201204346A (en) Novel hydroxamic acid derivative
US11236086B2 (en) Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
AU2023358081A1 (en) Novel bicyclic heterocyclyl compounds and use thereof
BR112020013141A2 (pt) óxi-fluoropiperidina como inibidor de quinase
EA019488B1 (ru) Ингибиторы limk2 и способы их применения
WO2021079196A2 (en) Mettl3 modulators
RS62271B1 (sr) Inhibitori 3-fosfoglicerat dehidrogenaze i njihova upotreba
US20250019374A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
EP3400226A1 (en) Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
CA3168222A1 (en) Pyrrolopyrimidine derivatives and pharmaceutical composition for preventing or treating protein kinase-related disease comprising the same as an active ingredient
US20240092761A1 (en) Quinazoline compounds and methods of use
AU2022386164A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
JPWO2011102404A1 (ja) イミダゾール誘導体
WO2019022235A1 (ja) 円形脱毛症の治療剤又は予防剤
TWI652265B (zh) 氮雜吲哚衍生物
AU2020421654A1 (en) RORγt inhibitor, preparation method thereof and use thereof
CA3070717C (en) Inhibitors of plasma kallikrein and uses thereof